TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3557779

Group type: EXPERIMENTAL
Intervention: Training for 14 h/week
Number of subjects: 38

Group type: COMPARATOR
Intervention: Training for 7 h/week
Number of subjects: 38
Study: 31696260

Group type: EXPERIMENTAL
Intervention: Vitamin E blended highly cross-linked ultra-high molecular weight polyethylene liners (UHMWPE‐XE)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Conventional highly cross-linked polyethylene liners (UHMWPE‑X)
Number of subjects: 143
Study: 30670102

Group type: EXPERIMENTAL
Intervention: Web-based intervention plus TIPs for 12 weeks
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Web-based intervention plus text-message-initiated assessment of alcohol consumption for 12 weeks
Number of subjects: 1076

Group type: EXPERIMENTAL
Intervention: Web-based intervention only
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Alcohol-related psychoeducation
Number of subjects: 1076
Study: 29658242

Group type: EXPERIMENTAL
Intervention: 2 Hz TEAS
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: 100 Hz TEAS
Number of subjects: 72
Study: 25774807

Group type: EXPERIMENTAL
Intervention: Self-regulatory treatment (experimental group)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Educational hand hygiene leaflets (control group)
Number of subjects: 307
Study: 23321647

Group type: EXPERIMENTAL
Intervention: β‐blockade and losartan (BB-L)
Number of subjects: 28

Group type: COMPARATOR
Intervention: β‐blockade (BB)
Number of subjects: 28
Study: 20795875

Group type: EXPERIMENTAL
Intervention: PMT present video information
Number of subjects: 71

Group type: COMPARATOR
Intervention: Non-PMT information about ankle sprains
Number of subjects: 71

Group type: COMPARATOR
Intervention: No formal information
Number of subjects: 71
Study: 19820133

Group type: EXPERIMENTAL
Intervention: Baseline C-reactive protein (CRP) in the fourth quartile
Number of subjects: 3795

Group type: EXPERIMENTAL
Intervention: Worsening renal function
Number of subjects: 3795
Study: 16741212

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15063959

Group type: EXPERIMENTAL
Intervention: Oral solution misoprostol 400 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Oral tablet misoprostol 400 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Rectal misoprostol 400 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Vaginal misoprostol 400 microg
Number of subjects: 50

Group type: COMPARATOR
Intervention: Intramuscular syntometrine 1 ml
Number of subjects: 50
Study: 11213881

Group type: EXPERIMENTAL
Intervention: Graftskin
Number of subjects: 208

Group type: COMPARATOR
Intervention: Control (saline-moistened gauze)
Number of subjects: 208
Study: 9562133

Group type: EXPERIMENTAL
Intervention: Gabapentin mixed with fat-free chocolate pudding (phase IV)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Gabapentin (control, phase I)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Gabapentin mixed with protein (phase IV)
Number of subjects: 9
Study: 7515453

Group type: EXPERIMENTAL
Intervention: Combined administration of 100 to 250 micrograms/day of G‐CSF, 400 to 800 mg/day of MCZ, and various antibiotics (Group I)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Combined administration of 400 to 800 mg/day of MCZ, 100 to 250 micrograms/day of G‐CSF, and various antibiotics (Group II)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combined administration of 200 to 1,200 mg/day of MCZ and various antibiotics (Group III)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Combined administration of 400 to 800 mg/day of MCZ and various antibiotics (Group III)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: G‐CSF administration in 7 patients
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: MCZ and antibiotics
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Therapeutic modality
Number of subjects: 15
Study: 3334047

Group type: EXPERIMENTAL
Intervention: Dynamic bone alignment device (group A)
Number of subjects: 116

Group type: COMPARATOR
Intervention: Manual reduction with local infiltration anaesthesia (group B)
Number of subjects: 116
Study: 29131316

Group type: EXPERIMENTAL
Intervention: HBV screening and vaccination multicomponent intervention
Number of subjects: 1834

Group type: COMPARATOR
Intervention: General cancer education control
Number of subjects: 1834
Study: 27168267

Group type: EXPERIMENTAL
Intervention: Stem cell-derived skin lineage precursor secretions incorporated in serum and lotion
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (placebo or standard treatment not specified)
Number of subjects: 50
Study: 25024196

Group type: EXPERIMENTAL
Intervention: Strategies leading to asymmetric payoffs played by participants from India
Number of subjects: 1000

Group type: COMPARATOR
Intervention: Strategies leading to symmetric payoffs played by participants from the United States
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Prompted to play asymmetrically by participants from India
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Matching with other study participants from their own population
Number of subjects: 1000
Study: 22670050

Group type: EXPERIMENTAL
Intervention: 2009-2010 seasonal trivalent inactivated influenza vaccine (TIV)
Number of subjects: 796
Study: 20576697

Group type: EXPERIMENTAL
Intervention: Progressive supranuclear palsy group
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy group
Number of subjects: 683

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 683
Study: 18702556

Group type: EXPERIMENTAL
Intervention: Incredible Years Parent Training Program with developmental delay modifications (12-week duration)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Usual care (including early childhood education and related services)
Number of subjects: 44
Study: 15702297

Group type: COMPARATOR
Intervention: Conventional dosimetry system (CONV)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Paris dosimetry system (PDS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Geometrically optimized system (GOS)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Conformal system (CONF)
Number of subjects: 17
Study: 12734690

Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) injection 10 min before the second dose of N-isopropyl-[123I] p-iodoamphetamine (IMP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Standard input function (F(SIF)) calibrated with continuously drawn arterial blood sample
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Standard input function (F(SIF)) calibrated with a single arterial blood sample
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dual-table ARG method
Number of subjects: 33
Study: 10227003

Group type: EXPERIMENTAL
Intervention: Systemic hormone replacement therapy (HRT)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Vaginal cream of estriol
Number of subjects: 62

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 62
Study: 8564973

Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. daily or every other day
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 175 mg/m2/day (liquid formulation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 125 mg/m2/day (gelatin capsule formulation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI) administered p.o. at 330 mg/m2 every‐other‐day (liquid formulation)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Carboxyamido‐triazole (CAI)
Number of subjects: 49
Study: 1715153

Group type: EXPERIMENTAL
Intervention: Maternal VDRL titre of 1:32 or above
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated mothers
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low birthweight
Number of subjects: 0
Study: 6137227

Group type: EXPERIMENTAL
Intervention: Midazolam 0.075 mg kg‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Diazepam 0.15 mg kg‐1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Comparison between Midazolam and Diazepam
Number of subjects: 0
Study: 30721964

Group type: EXPERIMENTAL
Intervention: Histologic improvement defined by absence of erosion or ulceration, absence of crypt destruction, and <5% of crypts with epithelial neutrophil infiltration in the PURSUIT‐SC trial.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 8 in JAK‐UC trial.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 4 in JAK‐UC trial.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Histologic improvement at Week 6 in PROgECT trial.
Number of subjects: 420
Study: 30521632

Group type: EXPERIMENTAL
Intervention: Messages focused on personal agency
Number of subjects: 12316

Group type: COMPARATOR
Intervention: Messages focused on communion
Number of subjects: 12316
Study: 26607941

Group type: EXPERIMENTAL
Intervention: Low-sugar diet (replacing 40% of calories from simple sugars with fats, proteins, and complex carbohydrates)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-sugar diet
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (no change in sugar intake)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Low-sugar diet and Control group
Number of subjects: 33
Study: 24610180

Group type: EXPERIMENTAL
Intervention: Implicit association test before decision
Number of subjects: 543

Group type: COMPARATOR
Intervention: Black patient
Number of subjects: 543

Group type: COMPARATOR
Intervention: White patient
Number of subjects: 543

Group type: COMPARATOR
Intervention: Implicit racial bias
Number of subjects: 543

Group type: COMPARATOR
Intervention: Explicit racial bias
Number of subjects: 543

Group type: COMPARATOR
Intervention: Medical cooperativeness stereotypes
Number of subjects: 543
Study: 22584263

Group type: COMPARATOR
Intervention: Glyceryl glucoside (GG) 5% applied topically
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glyceryl glucoside (GG) 3% w/v in cultured human keratinocytes
Number of subjects: 0
Study: 20470272

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 17638394

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50mg twice daily
Number of subjects: 370

Group type: COMPARATOR
Intervention: Diclofenac 75mg twice daily
Number of subjects: 370
Study: 15618066

Group type: EXPERIMENTAL
Intervention: Early coronary angiography
Number of subjects: 1609

Group type: COMPARATOR
Intervention: Non-invasive treatment (no early coronary angiography)
Number of subjects: 1609
Study: 12901810

Group type: EXPERIMENTAL
Intervention: Protective plastic oral guard
Number of subjects: 34

Group type: COMPARATOR
Intervention: No guard (Control)
Number of subjects: 34
Study: 10326953

Group type: EXPERIMENTAL
Intervention: Topical ocular hypotensive medication
Number of subjects: 1637

Group type: COMPARATOR
Intervention: Close observation
Number of subjects: 1637
Study: 8547445

Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Thyrotropin-releasing hormone
Number of subjects: 8
Study: 1662959

Group type: EXPERIMENTAL
Intervention: 200 mg itraconazole once a day
Number of subjects: 111

Group type: COMPARATOR
Intervention: 200 mg ketoconazole twice a day
Number of subjects: 111
Study: 6161788

Group type: EXPERIMENTAL
Intervention: Alcohol 0.8 g/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xylene 1200 mg/m3 + Alcohol 0.8 g/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xylene 700 mg/m3 + Alcohol 0.8 g/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Xylene 1200 mg/m3 alone
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Alcohol alone (0.4 g/kg and 0.8 g/kg)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control days (no exposure)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lower exposure levels
Number of subjects: 8
Study: 30706836

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 1)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (Group 2)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg and valsartan 160 mg in the morning (Group 3)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Indapamide retard 1.5 mg in the morning and valsartan 80 mg twice a day (Group 4)
Number of subjects: 235

Group type: EXPERIMENTAL
Intervention: Double sartan therapy (Group 4)
Number of subjects: 235
Study: 28438151

Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no PRF)
Number of subjects: 30
Study: 25416329

Group type: EXPERIMENTAL
Intervention: LCZ696
Number of subjects: 0
Study: 25066025

Group type: EXPERIMENTAL
Intervention: PEG‐SD (Polyethylene glycol 3350 plus sports drink)
Number of subjects: 364

Group type: COMPARATOR
Intervention: PEG‐ELS (Polyethylene glycol with electrolyte solution)
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: PEG‐SD
Number of subjects: 364

Group type: COMPARATOR
Intervention: PEG‐ELS
Number of subjects: 364
Study: 22210755

Group type: EXPERIMENTAL
Intervention: Etravirine 400 mg once daily
Number of subjects: 157

Group type: COMPARATOR
Intervention: Efavirenz 600 mg once daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Abacavir/lamivudine
Number of subjects: 157

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 157
Study: 19542736

Group type: EXPERIMENTAL
Intervention: High responders (HR) to ACTH1-24
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intermediate responders (IR) to ACTH1-24
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Normal responders (NR) to ACTH1-24
Number of subjects: 90

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 90
Study: 17445476

Group type: EXPERIMENTAL
Intervention: Inhalation of 0.001% NO gas with air, twice daily (AM and PM each for an hour)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Routine medical treatment (oxygen, aminophylline, dexamethasone, and furosemide)
Number of subjects: 47
Study: 15006577

Group type: EXPERIMENTAL
Intervention: Video feedback alone
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Video feedback with the help of an expert
Number of subjects: 29

Group type: COMPARATOR
Intervention: No feedback
Number of subjects: 29
Study: 16624192

Group type: EXPERIMENTAL
Intervention: Dinoprostone (6 hourly intervals up to two doses)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Intracervical Foley catheter
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Misoprostol (50 microg oral, 4 hourly to a maximum of four doses)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: All three agents (Dinoprostone, Foley catheter, Misoprostol)
Number of subjects: 226
Study: 10545434

Group type: EXPERIMENTAL
Intervention: VVI pacing for 3 months
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Reestablishment of AV synchrony with DDD pacing after VVI pacing
Number of subjects: 30

Group type: COMPARATOR
Intervention: DDD pacing for 3 months
Number of subjects: 30
Study: 9026379

Group type: EXPERIMENTAL
Intervention: Pindolol 30 mg, p.o.
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 2068470

Group type: EXPERIMENTAL
Intervention: Clindamycin plus aztreonam (900 mg clindamycin + 1 g aztreonam)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Clindamycin plus cefotaxime (900 mg clindamycin + 1 g cefotaxime)
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Clindamycin plus aztreonam
Number of subjects: 312

Group type: EXPERIMENTAL
Intervention: Clindamycin plus cefotaxime
Number of subjects: 312

Group type: COMPARATOR
Intervention: Cefotaxime
Number of subjects: 312
Study: 6337676

Group type: EXPERIMENTAL
Intervention: PTFE (Goretex)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Human umbilical vein (Biograft)
Number of subjects: 104
Study: 31583951

Group type: EXPERIMENTAL
Intervention: Working Memory (WM) training group
Number of subjects: 31

Group type: COMPARATOR
Intervention: Treatment-as-usual (TAU) control group
Number of subjects: 31
Study: 28453221

Group type: EXPERIMENTAL
Intervention: Short implants (6 mm)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Long implants (10 mm)
Number of subjects: 2
Study: 26424170

Group type: EXPERIMENTAL
Intervention: Empagliflozin plus metformin
Number of subjects: 1545

Group type: COMPARATOR
Intervention: Glimepiride plus metformin
Number of subjects: 1545
Study: 25090264

Group type: EXPERIMENTAL
Intervention: Increasing the dose of metformin (500 mg/day)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Add-on sitagliptin (50 mg/day)
Number of subjects: 70
Study: 22147480

Group type: EXPERIMENTAL
Intervention: Ammonia concentration 12 mg/m3
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ammonia concentration 21 mg/m3
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Ammonia concentration 34 mg/m3
Number of subjects: 4

Group type: COMPARATOR
Intervention: Ammonia concentration 4 mg/m3
Number of subjects: 4
Study: 19714601

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Advice
Number of subjects: 259

Group type: EXPERIMENTAL
Intervention: Physiotherapist‐guided treatment
Number of subjects: 259
Study: 17065167

Group type: EXPERIMENTAL
Intervention: Oesophageal Doppler (OD) guided optimization of stroke volume (SV)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Modelflow SV
Number of subjects: 12

Group type: COMPARATOR
Intervention: Svo2
Number of subjects: 12

Group type: COMPARATOR
Intervention: FTc
Number of subjects: 12

Group type: COMPARATOR
Intervention: NIRS (muscle and brain oxygenation)
Number of subjects: 12
Study: 15008765

Group type: EXPERIMENTAL
Intervention: Atosiban
Number of subjects: 1431

Group type: COMPARATOR
Intervention: Hexoprenaline
Number of subjects: 1431
Study: 12411844

Group type: EXPERIMENTAL
Intervention: 111In labelled leukocytes (ILLs)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (6 male patients with urinary tract infections)
Number of subjects: 16
Study: 9656849

Group type: EXPERIMENTAL
Intervention: 10% carbamide peroxide bleaching paste
Number of subjects: 51

Group type: COMPARATOR
Intervention: Colgate Platinum Professional Overnight Whitening System
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Experimental agent group
Number of subjects: 51

Group type: COMPARATOR
Intervention: Colgate Platinum group
Number of subjects: 51
Study: 8607569

Group type: EXPERIMENTAL
Intervention: Loratadine
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 26
Study: 29355350

Group type: EXPERIMENTAL
Intervention: Alcoholic drink (n = 48)
Number of subjects: 94

Group type: COMPARATOR
Intervention: Placebo drink (n = 46)
Number of subjects: 94
Study: 28283282

Group type: EXPERIMENTAL
Intervention: docetaxel, prednisone, and custirsen
Number of subjects: 1022

Group type: COMPARATOR
Intervention: docetaxel and prednisone
Number of subjects: 1022
Study: 25673442

Group type: EXPERIMENTAL
Intervention: Mesh group
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nonmesh group
Number of subjects: 22
Study: 23215900

Group type: EXPERIMENTAL
Intervention: Perioperative care protocol based on The Surviving Sepsis Guidelines
Number of subjects: 629

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 629
Study: 21737063

Group type: EXPERIMENTAL
Intervention: Amine fluoride (Elmex fluid) with laser irradiation (G4)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cerium chloride with laser irradiation (G6)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined fluoride/cerium chloride application with laser irradiation (G8)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo (G1)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Amine fluoride (G3)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Cerium chloride (G5)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Combined cerium chloride and amine fluoride application (G7)
Number of subjects: 96
Study: 19934804

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (triamcinolone and lidocaine)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Saline injection (control)
Number of subjects: 36
Study: 17024943

Group type: EXPERIMENTAL
Intervention: Resin composite shades (G1‐Incisal; G2‐A1; G3‐A2; G4‐A3; G5‐A3.5; G6‐A4)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Enamel margins
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Dentin margins
Number of subjects: 60
Study: 12779069

Group type: EXPERIMENTAL
Intervention: Standard eradicating treatment
Number of subjects: 860

Group type: EXPERIMENTAL
Intervention: 1-month course of empirical treatment
Number of subjects: 860

Group type: COMPARATOR
Intervention: Functional dyspeptic patients without H. pylori infection
Number of subjects: 860
Study: 11060764

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide
Number of subjects: 0
Study: 9287924

Group type: EXPERIMENTAL
Intervention: Suprapubic catheterization
Number of subjects: 108

Group type: COMPARATOR
Intervention: Urethral catheterization
Number of subjects: 108
Study: 8308713

Group type: EXPERIMENTAL
Intervention: 1-mg capsule given twice daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: 1-mg tablet given twice daily
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 37
Study: 3330140

Group type: EXPERIMENTAL
Intervention: Azapropazone (days 1‐225)
Number of subjects: 93

Group type: COMPARATOR
Intervention: Indomethacin (1‐28) followed by Allopurinol (29‐225)
Number of subjects: 93
Study: 31573689

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion (beta-adrenergic agonist)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Meta-analysis including 724 participants
Number of subjects: 30
Study: 29802627

Group type: EXPERIMENTAL
Intervention: 1.2% Rosuvastatin gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: 1% Metformin gel
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 90
Study: 27244788

Group type: EXPERIMENTAL
Intervention: Students for Nutrition and Exercise intervention
Number of subjects: 1368

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 1368
Study: 24788320

Group type: EXPERIMENTAL
Intervention: Neomycin and rifaximin
Number of subjects: 31

Group type: COMPARATOR
Intervention: Neomycin and placebo
Number of subjects: 31
Study: 22356355

Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (standard treatment with ICS and LABA)
Number of subjects: 0